165 related articles for article (PubMed ID: 26632886)
1. The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis.
Nel M; Buys JM; Rautenbach R; Mowla S; Prince S; Heckmann JM
J Hum Genet; 2016 Apr; 61(4):307-16. PubMed ID: 26632886
[TBL] [Abstract][Full Text] [Related]
2. Association of transforming growth factor β-1 (TGFB1) regulatory region polymorphisms with myasthenia gravis-related ophthalmoparesis.
Akinyi MV; Dandara C; Gamieldien J; Heckmann JM
J Neuroimmunol; 2012 May; 246(1-2):96-9. PubMed ID: 22458981
[TBL] [Abstract][Full Text] [Related]
3. A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.
Heckmann JM; Uwimpuhwe H; Ballo R; Kaur M; Bajic VB; Prince S
Genes Immun; 2010 Jan; 11(1):1-10. PubMed ID: 19675582
[TBL] [Abstract][Full Text] [Related]
4. Exome sequencing identifies targets in the treatment-resistant ophthalmoplegic subphenotype of myasthenia gravis.
Nel M; Jalali Sefid Dashti M; Gamieldien J; Heckmann JM
Neuromuscul Disord; 2017 Sep; 27(9):816-825. PubMed ID: 28673556
[TBL] [Abstract][Full Text] [Related]
5. The functionality of African-specific variants in the TGFB1 regulatory region and their potential role in HIVAN.
Nel M; Buys JM; Botha FCJ; Wearne N; Prince S; Heckmann JM
Clin Exp Nephrol; 2018 Aug; 22(4):764-772. PubMed ID: 29204904
[TBL] [Abstract][Full Text] [Related]
6. Profiling of patient-specific myocytes identifies altered gene expression in the ophthalmoplegic subphenotype of myasthenia gravis.
Nel M; Prince S; Heckmann JM
Orphanet J Rare Dis; 2019 Jan; 14(1):24. PubMed ID: 30696470
[TBL] [Abstract][Full Text] [Related]
7. A unique subphenotype of myasthenia gravis.
Heckmann JM; Nel M
Ann N Y Acad Sci; 2018 Jan; 1412(1):14-20. PubMed ID: 28984362
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of orbital muscles in treatment-resistant ophthalmoplegic myasthenia gravis.
Europa TA; Nel M; Heckmann JM
Orphanet J Rare Dis; 2020 Dec; 15(1):346. PubMed ID: 33308266
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases.
Europa TA; Nel M; Lebeko MR; Heckmann JM
IBRO Neurosci Rep; 2022 Jun; 12():297-302. PubMed ID: 35746973
[TBL] [Abstract][Full Text] [Related]
10. Genetic association and gene expression profiles of TGFB1 and the contribution of TGFB1 to otosclerosis susceptibility.
Priyadarshi S; Ray CS; Panda KC; Desai A; Nayak SR; Biswal NC; Ramchander PV
J Bone Miner Res; 2013 Dec; 28(12):2490-7. PubMed ID: 23703862
[TBL] [Abstract][Full Text] [Related]
11. The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: implications in myasthenia gravis.
Auret J; Abrahams A; Prince S; Heckmann JM
Neuromuscul Disord; 2014 Jun; 24(6):499-508. PubMed ID: 24703255
[TBL] [Abstract][Full Text] [Related]
12. Using Whole Genome Sequencing in an African Subphenotype of Myasthenia Gravis to Generate a Pathogenetic Hypothesis.
Nel M; Mulder N; Europa TA; Heckmann JM
Front Genet; 2019; 10():136. PubMed ID: 30881381
[TBL] [Abstract][Full Text] [Related]
13. A review of the histopathological findings in myasthenia gravis: Clues to the pathogenesis of treatment-resistance in extraocular muscles.
Europa TA; Nel M; Heckmann JM
Neuromuscul Disord; 2019 May; 29(5):381-387. PubMed ID: 31029532
[TBL] [Abstract][Full Text] [Related]
14. A link between promoter polymorphisms of the transforming growth factor β1 (TGFB1) and TGF-β1 receptor II (TGFBR2) genes and relapsing-remitting multiple sclerosis.
Grigorova A; Trenova A; Stanilova S
Folia Neuropathol; 2020; 58(4):307-316. PubMed ID: 33480235
[TBL] [Abstract][Full Text] [Related]
15. Allelic diversity in the TGFB1 regulatory region: characterization of novel functional single nucleotide polymorphisms.
Shah R; Rahaman B; Hurley CK; Posch PE
Hum Genet; 2006 Mar; 119(1-2):61-74. PubMed ID: 16369764
[TBL] [Abstract][Full Text] [Related]
16. Functional impact of sequence variation in the promoter region of TGFB1.
Healy J; Dionne J; Bélanger H; Larivière M; Beaulieu P; Labuda D; Sinnett D
Int J Cancer; 2009 Sep; 125(6):1483-9. PubMed ID: 19536820
[TBL] [Abstract][Full Text] [Related]
17. No effect of the transforming growth factor β1 promoter polymorphism C-509T on TGFB1 gene expression, protein secretion, or cellular radiosensitivity.
Reuther S; Metzke E; Bonin M; Petersen C; Dikomey E; Raabe A
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):460-5. PubMed ID: 22592044
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta 1 polymorphisms and haplotypes associated with breast cancer susceptibility: A case-control study in Tunisian women.
Hadj-Ahmed M; Ghali RM; Bouaziz H; Habel A; Stayoussef M; Ayedi M; Hachiche M; Rahal K; Yacoubi-Loueslati B; Almawi WY
Tumour Biol; 2019 Aug; 41(8):1010428319869096. PubMed ID: 31405342
[TBL] [Abstract][Full Text] [Related]
19. Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.
Yang HW; Lei P; Xie YC; Han ZL; Li D; Wang SH; Sun ZL
Cancer Gene Ther; 2017 Jun; 24(6):259-266. PubMed ID: 28429750
[TBL] [Abstract][Full Text] [Related]
20. TGFB1 Functional Gene Polymorphisms (C-509T and T869C) in the Maternal Susceptibility to Pre-eclampsia in South Indian Women.
Deepthi G; Chaithri PK; Latha P; Rani VU; Rahman PF; Jahan P
Scand J Immunol; 2015 Oct; 82(4):390-7. PubMed ID: 26173679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
